Fig. 2From: Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitorsFrequency of positive answers of the ST-ICI cohort depending on clinician-reported irAE. a Gastrointestinal irAE. b Pulmonary irAE. c Endocrine irAE. d Skin irAE. e Hepatic irAE. f Neurologic irAE. g Renal irAE. h Non-specific irAEBack to article page